Abstract
Novel methods to treat HF include gene, cell and microRNA delivery. There have been few gene therapy trials in HF. The CUPID I and II trials with AAV1.SERCA2a showed unconvincing results. The STOP-HF trial using direct intra-myocardial injection of a non-integrating plasmid vector carrying stromal cell-derived factor-1 showed no clinical effects and the AC6 gene transfer trial used IC infusion of escalating doses of Ad5.hAC6 was similarly negative. Despite high hopes stem cell trials to date in HF have not shown convincing clinical benefits. More recent clinical trials in this area have investigated the injection of cell stimulating paracrine factors (peptides, small molecules, hormone-like molecules) without actual cell delivery. Micro-RNA’s (miRNAs) are small non-coding RNA strands, comprising 19-25 nucleotides, that have a distinct signalling role and a various patterns of expression in ischaemic myocardium, hypertrophy, cardiomyopathies, and overt HF. They act at the post-transcriptional regulation level. Numerous novel miRNAs have been discovered, and their in-depth role has been characterised. miRNAs can serve as therapeutic substances or therapeutic targets in a range of cardiovascular diseases. Clinical trials are likely in the near future.
Highlights
Cardiac gene therapies Recently, novel methods have emerged that have widened the opportunities to employ a gene therapeutic approach in the treatment of cardiovascular diseases
The first human clinical trials employing gene therapy in the cardiovascular field were performed with an adenoviral vector (AAV)
Penny and Hammond have reviewed gene based therapy for heart failure (HF) by searching PubMed and ClinicalTrials.gov for clinical trials published between January 1990 and October 2016, using the search terms “gene transfer” and “heart failure” and related terms.[2]
Summary
Cardiac gene therapies Recently, novel methods have emerged that have widened the opportunities to employ a gene therapeutic approach in the treatment of cardiovascular diseases. The first human clinical trials employing gene therapy in the cardiovascular field were performed with an adenoviral vector (AAV).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
